BioNTech Investor Day Presentation Deck
BNT221: NEO-STIM is an individualized neoantigen-targeted strategy
that addresses the limitations of tumor-infiltrating lymphocyte therapies
Targets each patient's multiple tumor neoantigens¹
Tumor
Sample/Sequencing
●
RÉCON
ARMATIES
Bioinformatics
A jos
+0°
Personalized
Immunogen Synthesis
(Peptide or RNA)
Leukapheresis
888
Culture
Reagents
APCs &
T cells
T cell
Epitopes
Prime
NEO.com
STIM
Activate
Specific Cell Subsets
From a Patient's
Apheresis Product
Expand
BNT221 Product
Multi-target: reduced risk for antigen escape
T cells are induced from peripheral blood
with no gene engineering or viral vectors: reduced toxicity
Broad clinical opportunity across solid tumors
¹ Velez D, et al. SITC Annual Meeting 2021, Poster presentation 201; 2 Lenkala D, et al. SITC Annual Meeting 2020, Poster presentation 153.
IFNY* and/or CD107a+
(of CD8+ pMHC*)
BNT221 cells specifically
recognize autologous tumor²
15
10
0
Cytokine response
T
BNT221
**
BNT221 +
autologous tumor
Cell therapies
BIONTECH
139View entire presentation